原发性和继发性肝脏肿瘤经动脉化疗栓塞及钇-90选择性内放疗期间12例动脉夹层的处理
该单中心回顾性研究分析了2010年5月至2015年6月间1377例次肝脏动脉造影(用于TACE和90Y SIRT),共记录12例动脉夹层(0.87%)。首选处理策略为越过夹层完成操作(6例成功),部分病例可延迟治疗最多3个月待夹层愈合。作者认为动脉夹层是罕见但重要的并发症,应尽可能完成治疗。
要点
- 动脉夹层总体发生率为0.87%(12/1377),其中90Y SIRT治疗前计划性造影(PTPA)发生率最高(1.56%)。
- 首选处理是越过夹层完成操作,本组6例(50%)成功;1例接受球囊血管成形术并支架置入。
- 3例延迟最多3个月后重复操作,随访未见残留夹层或临床后遗症;1例随访血管造影见50%残留狭窄但无症状。
关键影像表现/征象
- 共记录12例动脉夹层(12/1377,0.87%)。
- TACE期间发生3例(3/633,0.47%),90Y SIRT治疗前计划性造影(PTPA)期间发生7例(7/449,1.56%),90Y SIRT治疗操作期间发生2例(2/249,0.80%)。
- 1例PTPA期间发生的夹层在患者返回行90Y SIRT时才被发现,该患者立即重复了PTPA。
- 1例随访肝动脉造影见50%残留狭窄,但患者无症状;其余患者随访未见残留夹层或临床后遗症。
临床应用与阅片要点
- 首选处理策略是越过夹层并完成操作,本组6例(50%)成功。
- 1例接受了球囊血管成形术并支架置入。
- 3例暂停操作最多3个月以允许夹层愈合后再重复操作。
- 最后1例患者选择了索拉非尼治疗。
- 作者认为应尽可能尝试完成治疗;可考虑延迟治疗,因为夹层通常在3个月内愈合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To describe rates and management strategies of arterial dissections in transarterial chemoembolization (TACE) and Yttrium-90 selective internal radiotherapy (90Y SIRT) for primary and secondary liver tumours.
MATERIALS AND METHODS: This retrospective review included 1377 hepatic angiographies between May 2010 and June 2015 in a single centre for TACE and 90Y SIRT of liver tumours. The angiogram results, management, treatment outcomes and follow-up angiography/imaging findings were recorded.
RESULTS AND DISCUSSION: Twelve cases of arterial dissections (12/1377, 0.87%) were documented. Three dissections (3/633, 0.47%) occurred during TACE, seven (7/449, 1.56%) during pre-treatment planning angiographies (PTPA) for 90Y SIRT, and two (2/249, 0.80%) during the treatment procedure of 90Y SIRT. The preferred management strategy was to manoeuvre past the dissection and complete the procedure, which was achieved in six patients (50%). Angioplasty with stenting was performed in one patient. In three patients, the procedure was held off for up to 3 months to allow the dissection to heal before repeating the procedure. A dissection that occurred during PTPA was detected only when the patient returned for 90Y SIRT. PTPA was immediately repeated for this patient. The last patient opted for sorafenib. Residual 50% stenosis was seen in one patient on follow-up hepatic angiography, but he was otherwise asymptomatic. In the remaining patients, no residual dissection or clinical sequelae was observed on follow-up.
CONCLUSION: Arterial dissection is a rare but important complication of transarterial locoregional therapy. Where possible, attempts should be made at completing the therapy. Deferring treatment can be considered as dissections usually heal within 3 months.
LEVEL OF EVIDENCE: Level 4, case series.
引用
- Goh WXT, Too CW, Lee KA, et al. Management of arterial dissections in 12 patients during transarterial chemoembolization and yttrium-90 selective internal radiotherapy for primary and secondary liver tumours. Abdom Radiol (NY). 2020. PMID: 33052468. doi:10.1007/s00261-020-02810-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。